{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:09:32Z","timestamp":1780117772987,"version":"3.54.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The authors acknowledge the Deanship of Scientific Research at King Faisal university for financial support under Nasher track"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sorafenib (SO) is a multi-kinase inhibitor that targets upstream signals in the MAPK pathway. Drug resistance and transient survival benefits are the main obstacles associated with SO treatment in Hepatocellular carcinoma (HCC) patients. Mebendazole (MBZ), an anthelmintic agent, has demonstrated activity against various cancer types. Therefore, we aimed to investigate the possible mechanisms of MBZ other than its anti-tubulin activity. MBZ (100\u2009mg\/kg\/day, P.O.) was administered to N-nitrosodiethylamine-induced HCC mice as a monotherapeutic agent or in combination with SO. Our results revealed that MBZ decreased AFP levels, improved liver function and histology and increased survival in HCC mice, particularly when administered in combination with SO. MBZ also reduced hepatic inflammation and fibrogenesis as evidenced by reductions in TNF-\u03b1 and TGF-\u03b21 levels, respectively. Increased hepatic caspases-3 and -9 and decreased BCL-2 levels suggest induced-cell death. In addition, MBZ demonstrated anti-angiogenic, anti-metastatic, and anti-proliferative effects, as indicated by reduced VEGF levels, MMP-2:TIMP-1 ratios, and reduced cyclin D1 levels and Ki67 immunostaining, respectively. Our main finding was that MBZ targeted downstream signal of the MAPK pathway by inhibiting ERK1\/2 phosphorylation. Targeting downstream MAPK signalling by MBZ and upstream signalling by SO is a novel approach to minimizing resistance and prolonging survival.<\/jats:p>","DOI":"10.1038\/s41598-019-55666-x","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T11:04:00Z","timestamp":1576235040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4309-7095","authenticated-orcid":false,"given":"Nancy S.","family":"Younis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal M. H.","family":"Ghanim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameh","family":"Saber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,13]]},"reference":[{"key":"55666_CR1","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/ijcp.12352","volume":"68","author":"R Lencioni","year":"2014","unstructured":"Lencioni, R. et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. International journal of clinical practice 68, 609\u2013617 (2014).","journal-title":"International journal of clinical practice"},{"key":"55666_CR2","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer 127, 2893\u20132917 (2010).","journal-title":"International journal of cancer"},{"key":"55666_CR3","first-page":"69","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal, A. et al. Global cancer statistics. CA: a cancer journal for clinicians 61, 69\u201390 (2011).","journal-title":"CA: a cancer journal for clinicians"},{"key":"55666_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1677\/erc.0.0080219","volume":"8","author":"J Lyons","year":"2001","unstructured":"Lyons, J., Wilhelm, S., Hibner, B. & Bollag, G. Discovery of a novel Raf kinase inhibitor. Endocrine-related cancer 8, 219\u2013225 (2001).","journal-title":"Endocrine-related cancer"},{"key":"55666_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.canlet.2013.12.028","volume":"346","author":"A Galmiche","year":"2014","unstructured":"Galmiche, A., Chauffert, B. & Barbare, J.-C. New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma. Cancer letters 346, 159\u2013162 (2014).","journal-title":"Cancer letters"},{"key":"55666_CR6","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1111\/liv.12818","volume":"35","author":"JW Park","year":"2015","unstructured":"Park, J. W. et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver International 35, 2155\u20132166 (2015).","journal-title":"Liver International"},{"key":"55666_CR7","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.2147\/OTT.S161023","volume":"11","author":"Y Wang","year":"2018","unstructured":"Wang, Y., Gou, Q., Xu, R., Chen, X. & Zhou, Z. efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: a comparative retrospective study. OncoTargets and therapy 11, 3407 (2018).","journal-title":"OncoTargets and therapy"},{"key":"55666_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2015.06.019","volume":"367","author":"J Chen","year":"2015","unstructured":"Chen, J. et al. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer letters 367, 1\u201311 (2015).","journal-title":"Cancer letters"},{"key":"55666_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2147\/JHC.S124366","volume":"4","author":"EM Ray","year":"2017","unstructured":"Ray, E. M. & Sanoff, H. K. Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions. Journal of hepatocellular carcinoma 4, 131 (2017).","journal-title":"Journal of hepatocellular carcinoma"},{"key":"55666_CR10","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.3892\/ol.2016.5110","volume":"12","author":"L Li","year":"2016","unstructured":"Li, L. et al. The Ras\/Raf\/MEK\/ERK signaling pathway and its role in the occurrence and development of HCC. Oncology letters 12, 3045\u20133050 (2016).","journal-title":"Oncology letters"},{"key":"55666_CR11","unstructured":"Dhillion, A. S., Hagan, S., Rath, O. & Kolch, W. (PMID, 2007)."},{"key":"55666_CR12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.ccr.2004.09.028","volume":"6","author":"A Sparmann","year":"2004","unstructured":"Sparmann, A. & Bar-Sagi, D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer cell 6, 447\u2013458 (2004).","journal-title":"Cancer cell"},{"key":"55666_CR13","unstructured":"Gollob, J. A., Wilhelm, S., Carter, C. & Kelley, S. L. In Seminars in oncology. 392\u2013406 (Elsevier)."},{"key":"55666_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.canlet.2009.01.022","volume":"283","author":"C Montagut","year":"2009","unstructured":"Montagut, C. & Settleman, J. Targeting the RAF\u2013MEK\u2013ERK pathway in cancer therapy. Cancer letters 283, 125\u2013134 (2009).","journal-title":"Cancer letters"},{"key":"55666_CR15","first-page":"511","volume":"45","author":"R Abdel-Ghany","year":"2015","unstructured":"Abdel-Ghany, R. et al. Blockade of PGE2, PGD2 Receptors Confers Protection against Prepatent Schistosomiasis Mansoni in Mice. Journal of the Egyptian Society of Parasitology 45, 511\u2013520 (2015).","journal-title":"Journal of the Egyptian Society of Parasitology"},{"key":"55666_CR16","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","volume":"1773","author":"JA McCubrey","year":"2007","unstructured":"McCubrey, J. A. et al. Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1773, 1263\u20131284 (2007).","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular Cell Research"},{"key":"55666_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-3-19","volume":"3","author":"H Huynh","year":"2003","unstructured":"Huynh, H. et al. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC gastroenterology 3, 19 (2003).","journal-title":"BMC gastroenterology"},{"key":"55666_CR18","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.12659\/MSM.909621","volume":"24","author":"S Huang","year":"2018","unstructured":"Huang, S. et al. Overexpression of the Ubiquilin-4 (UBQLN4) is Associated with Cell Cycle Arrest and Apoptosis in Human Normal Gastric Epithelial Cell Lines GES-1 Cells by Activation of the ERK Signaling Pathway. Medical science monitor: international medical journal of experimental and clinical research 24, 3564 (2018).","journal-title":"Medical science monitor: international medical journal of experimental and clinical research"},{"key":"55666_CR19","doi-asserted-by":"publisher","first-page":"6005","DOI":"10.3748\/wjg.v18.i42.6005","volume":"18","author":"M Kudo","year":"2012","unstructured":"Kudo, M. Signaling pathway\/molecular targets and new targeted agents under development in hepatocellular carcinoma. World journal of gastroenterology: WJG 18, 6005 (2012).","journal-title":"World journal of gastroenterology: WJG"},{"key":"55666_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/2045-3701-1-42","volume":"1","author":"DA Chapnick","year":"2011","unstructured":"Chapnick, D. A., Warner, L., Bernet, J., Rao, T. & Liu, X. Partners in crime: the TGF\u03b2 and MAPK pathways in cancer progression. Cell & bioscience 1, 42 (2011).","journal-title":"Cell & bioscience"},{"key":"55666_CR21","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/aps.2014.130","volume":"36","author":"H-j Zhao","year":"2015","unstructured":"Zhao, H.-j et al. Fructus phyllanthi tannin fraction induces apoptosis and inhibits migration and invasion of human lung squamous carcinoma cells in vitro via MAPK\/MMP pathways. Acta Pharmacologica Sinica 36, 758 (2015).","journal-title":"Acta Pharmacologica Sinica"},{"key":"55666_CR22","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nrd4281","volume":"13","author":"AA Samatar","year":"2014","unstructured":"Samatar, A. A. & Poulikakos, P. I. Targeting RAS\u2013ERK signalling in cancer: promises and challenges. Nature reviews Drug discovery 13, 928 (2014).","journal-title":"Nature reviews Drug discovery"},{"key":"55666_CR23","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1158\/2159-8290.CD-14-1518","volume":"5","author":"LG Ahronian","year":"2015","unstructured":"Ahronian, L. G. et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer discovery 5, 358\u2013367 (2015).","journal-title":"Cancer discovery"},{"key":"55666_CR24","doi-asserted-by":"crossref","unstructured":"Liu, F., Yang, X., Geng, M. & Huang, M. Targeting ERK, an Achilles\u2019 Heel of the MAPK pathway, in cancer therapy. Acta Pharmaceutica Sinica B (2018).","DOI":"10.1016\/j.apsb.2018.01.008"},{"key":"55666_CR25","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/neuonc\/nor077","volume":"13","author":"R-Y Bai","year":"2011","unstructured":"Bai, R.-Y., Staedtke, V., Aprhys, C. M., Gallia, G. L. & Riggins, G. J. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro-oncology 13, 974\u2013982 (2011).","journal-title":"Neuro-oncology"},{"key":"55666_CR26","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1158\/1541-7786.MCR-07-2159","volume":"6","author":"N Doudican","year":"2008","unstructured":"Doudican, N., Rodriguez, A., Osman, I. & Orlow, S. J. Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Molecular Cancer Research 6, 1308\u20131315 (2008).","journal-title":"Molecular Cancer Research"},{"key":"55666_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.yexcr.2018.05.006","volume":"369","author":"L He","year":"2018","unstructured":"He, L. et al. Mebendazole exhibits potent anti-leukemia activity on acute myeloid leukemia. Experimental cell research 369, 61\u201368 (2018).","journal-title":"Experimental cell research"},{"key":"55666_CR28","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.intimp.2018.09.021","volume":"64","author":"S Saber","year":"2018","unstructured":"Saber, S., Goda, R., El-Tanbouly, G. S. & Ezzat, D. Lisinopril inhibits nuclear transcription factor kappa B and augments sensitivity to silymarin in experimental liver fibrosis. International Immunopharmacology 64, 340\u2013349, https:\/\/doi.org\/10.1016\/j.intimp.2018.09.021 (2018).","journal-title":"International Immunopharmacology"},{"key":"55666_CR29","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1053\/jhep.2000.9774","volume":"32","author":"I Fabregat","year":"2000","unstructured":"Fabregat, I. et al. Epidermal Growth Factor Impairs the Cytochrome C\/Caspase\u20103 Apoptotic Pathway Induced by Transforming Growth Factor \u03b2 in Rat Fetal Hepatocytes Via a Phosphoinositide 3\u2010Kinase\u2013Dependent Pathway. Hepatology 32, 528\u2013535 (2000).","journal-title":"Hepatology"},{"key":"55666_CR30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical biochemistry 72, 248\u2013254 (1976).","journal-title":"Analytical biochemistry"},{"key":"55666_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.toxlet.2018.05.036","volume":"295","author":"S Saber","year":"2018","unstructured":"Saber, S. et al. Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B. Toxicology Letters 295, 32\u201340, https:\/\/doi.org\/10.1016\/j.toxlet.2018.05.036 (2018).","journal-title":"Toxicology Letters"},{"issue":"6","key":"55666_CR32","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3889\/oamjms.2018.167","volume":"6","author":"Sameh Saber","year":"2018","unstructured":"Saber, S., Mahmoud, A., Helal, N., El-Ahwany, E. & Abdelghany, R. Liver Protective Effects of Renin-Angiotensin System Inhibition Have No Survival Benefits in Hepatocellular Carcinoma Induced By Repetitive Administration of Diethylnitrosamine in Mice. 2018 6, https:\/\/doi.org\/10.3889\/oamjms.2018.167 (2018).","journal-title":"Open Access Macedonian Journal of Medical Sciences"},{"key":"55666_CR33","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1158\/0008-5472.CAN-14-3687","volume":"75","author":"EA Kuczynski","year":"2015","unstructured":"Kuczynski, E. A., Lee, C. R., Man, S., Chen, E. & Kerbel, R. S. Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma. Cancer Res 75, 2510\u20132519, https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3687 (2015).","journal-title":"Cancer Res"},{"key":"55666_CR34","doi-asserted-by":"crossref","unstructured":"Pantziarka, P., Bouche, G., Meheus, L., Sukhatme, V. & Sukhatme, V. P. Repurposing Drugs in Oncology (ReDO)\u2014mebendazole as an anti-cancer agent. ecancermedicalscience 8 (2014).","DOI":"10.3332\/ecancer.2014.485"},{"key":"55666_CR35","unstructured":"Bosman, F. T., Carneiro, F., Hruban, R. H. & Theise, N. D. WHO classification of tumours of the digestive system. (World Health Organization, 2010)."},{"key":"55666_CR36","doi-asserted-by":"publisher","first-page":"413","DOI":"10.4194\/1303-2712-v14_2_11","volume":"14","author":"W Abdo","year":"2014","unstructured":"Abdo, W., Ghattas, S., Sakai, H., Hirata, A. & Yanai, T. Assessment of proliferative activity by proliferative cell nuclear antigen (PCNA) and anti-bromodeoxyuridine (BrdU) immunolabeling in the tissues of japanese eels (Anguilla japonica). Turkish Journal of Fisheries and Aquatic Sciences 14, 413\u2013419 (2014).","journal-title":"Turkish Journal of Fisheries and Aquatic Sciences"},{"key":"55666_CR37","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3892\/ol.2017.5557","volume":"13","author":"S Yang","year":"2017","unstructured":"Yang, S. & Liu, G. Targeting the Ras\/Raf\/MEK\/ERK pathway in hepatocellular carcinoma. Oncology letters 13, 1041\u20131047 (2017).","journal-title":"Oncology letters"},{"key":"55666_CR38","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nrclinonc.2011.30","volume":"8","author":"AX Zhu","year":"2011","unstructured":"Zhu, A. X., Duda, D. G., Sahani, D. V. & Jain, R. K. HCC and angiogenesis: possible targets and future directions. Nature reviews Clinical oncology 8, 292 (2011).","journal-title":"Nature reviews Clinical oncology"},{"key":"55666_CR39","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/cr.2009.5","volume":"19","author":"J Xu","year":"2009","unstructured":"Xu, J., Lamouille, S. & Derynck, R. TGF-\u03b2-induced epithelial to mesenchymal transition. Cell research 19, 156 (2009).","journal-title":"Cell research"},{"key":"55666_CR40","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1139\/cjpp-2017-0728","volume":"96","author":"S Saber","year":"2018","unstructured":"Saber, S., Mahmoud, A. A. A., Helal, N. S., El-Ahwany, E. & Abdelghany, R. H. Renin\u2013angiotensin system inhibition ameliorates CCl4-induced liver fibrosis in mice through the inactivation of nuclear transcription factor kappa B. Canadian Journal of Physiology and Pharmacology 96, 569\u2013576, https:\/\/doi.org\/10.1139\/cjpp-2017-0728 (2018).","journal-title":"Canadian Journal of Physiology and Pharmacology"},{"key":"55666_CR41","doi-asserted-by":"publisher","first-page":"21614","DOI":"10.18632\/oncotarget.4308","volume":"6","author":"M Serova","year":"2015","unstructured":"Serova, M. et al. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Oncotarget 6, 21614 (2015).","journal-title":"Oncotarget"},{"key":"55666_CR42","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/ijc.1635","volume":"97","author":"G Giannelli","year":"2002","unstructured":"Giannelli, G. et al. Clinical role of MMP\u20102\/TIMP\u20102 imbalance in hepatocellular carcinoma. International journal of cancer 97, 425\u2013431 (2002).","journal-title":"International journal of cancer"},{"key":"55666_CR43","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/jcp.20616","volume":"207","author":"L Kuo","year":"2006","unstructured":"Kuo, L., Chang, H. C., Leu, T. H., Maa, M. C. & Hung, W. C. Src oncogene activates MMP\u20102 expression via the ERK\/Sp1 pathway. Journal of cellular physiology 207, 729\u2013734 (2006).","journal-title":"Journal of cellular physiology"},{"key":"55666_CR44","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.canlet.2015.07.035","volume":"368","author":"L Qian","year":"2015","unstructured":"Qian, L. et al. Matrine derivative WM130 inhibits hepatocellular carcinoma by suppressing EGFR\/ERK\/MMP-2 and PTEN\/AKT signaling pathways. Cancer letters 368, 126\u2013134 (2015).","journal-title":"Cancer letters"},{"key":"55666_CR45","doi-asserted-by":"publisher","first-page":"68571","DOI":"10.18632\/oncotarget.11851","volume":"7","author":"T Williamson","year":"2016","unstructured":"Williamson, T., Bai, R.-Y., Staedtke, V., Huso, D. & Riggins, G. J. Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model. Oncotarget 7, 68571 (2016).","journal-title":"Oncotarget"},{"key":"55666_CR46","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.bios.2016.04.081","volume":"85","author":"H Shashaani","year":"2016","unstructured":"Shashaani, H. et al. Silicon nanowire based biosensing platform for electrochemical sensing of Mebendazole drug activity on breast cancer cells. Biosensors and Bioelectronics 85, 363\u2013370 (2016).","journal-title":"Biosensors and Bioelectronics"},{"key":"55666_CR47","doi-asserted-by":"publisher","first-page":"12576","DOI":"10.18632\/oncotarget.14990","volume":"8","author":"CM Simbulan-Rosenthal","year":"2017","unstructured":"Simbulan-Rosenthal, C. M. et al. The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma. Oncotarget 8, 12576 (2017).","journal-title":"Oncotarget"},{"key":"55666_CR48","doi-asserted-by":"publisher","first-page":"351","DOI":"10.15171\/apb.2015.049","volume":"5","author":"S Sharifi","year":"2015","unstructured":"Sharifi, S., Barar, J., Hejazi, M. S. & Samadi, N. Doxorubicin changes Bax\/Bcl-xL ratio, caspase-8 and 9 in breast cancer cells. Advanced pharmaceutical bulletin 5, 351 (2015).","journal-title":"Advanced pharmaceutical bulletin"},{"key":"55666_CR49","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.3892\/etm.2016.3655","volume":"12","author":"K Zhang","year":"2016","unstructured":"Zhang, K. et al. OMP31 of Brucella melitensis 16M impairs the apoptosis of macrophages triggered by TNF-\u03b1. Experimental and therapeutic medicine 12, 2783\u20132789 (2016).","journal-title":"Experimental and therapeutic medicine"},{"key":"55666_CR50","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3390\/biom9080346","volume":"9","author":"SH Aladaileh","year":"2019","unstructured":"Aladaileh, S. H. et al. Galangin Activates Nrf2 Signaling and Attenuates Oxidative Damage, Inflammation, and Apoptosis in a Rat Model of Cyclophosphamide-Induced Hepatotoxicity. Biomolecules 9, 346 (2019).","journal-title":"Biomolecules"},{"key":"55666_CR51","doi-asserted-by":"crossref","unstructured":"Abdel-Magied, N. & Elkady, A. A. Possible curative role of curcumin and silymarin against nephrotoxicity induced by gamma-rays in rats. Experimental and molecular pathology, 104299 (2019).","DOI":"10.1016\/j.yexmp.2019.104299"},{"key":"55666_CR52","doi-asserted-by":"publisher","first-page":"e22201","DOI":"10.1002\/jbt.22201","volume":"32","author":"EH Aksu","year":"2018","unstructured":"Aksu, E. H., Kandemir, F. M., K\u00fc\u00e7\u00fckler, S. & Mahamadu, A. Improvement in colistin\u2010induced reproductive damage, apoptosis, and autophagy in testes via reducing oxidative stress by chrysin. Journal of biochemical and molecular toxicology 32, e22201 (2018).","journal-title":"Journal of biochemical and molecular toxicology"},{"key":"55666_CR53","doi-asserted-by":"publisher","first-page":"e22254","DOI":"10.1002\/jbt.22254","volume":"33","author":"HI Ahmed","year":"2019","unstructured":"Ahmed, H. I. & Mohamed, E. A. Candesartan and epigallocatechin\u20103\u2010gallate ameliorate gentamicin\u2010induced renal damage in rats through p38\u2010MAPK and NF\u2010\u03baB pathways. Journal of biochemical and molecular toxicology 33, e22254 (2019).","journal-title":"Journal of biochemical and molecular toxicology"},{"key":"55666_CR54","doi-asserted-by":"publisher","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","volume":"66","author":"L Liu","year":"2006","unstructured":"Liu, L. et al. Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5. Cancer research 66, 11851\u201311858 (2006).","journal-title":"Cancer research"},{"key":"55666_CR55","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1177\/1947601913479022","volume":"3","author":"MC Casimiro","year":"2012","unstructured":"Casimiro, M. C., Crosariol, M., Loro, E., Li, Z. & Pestell, R. G. Cyclins and cell cycle control in cancer and disease. Genes & cancer 3, 649\u2013657 (2012).","journal-title":"Genes & cancer"},{"key":"55666_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-6-24","volume":"6","author":"JP Alao","year":"2007","unstructured":"Alao, J. P. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Molecular cancer 6, 24 (2007).","journal-title":"Molecular cancer"},{"key":"55666_CR57","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.4161\/cc.21193","volume":"11","author":"M Cervello","year":"2012","unstructured":"Cervello, M. et al. Molecular mechanisms of sorafenib action in liver cancer cells. Cell cycle 11, 2843\u20132855 (2012).","journal-title":"Cell cycle"},{"key":"55666_CR58","doi-asserted-by":"crossref","unstructured":"Yang, F. et al. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Molecular cancer therapeutics, 1535\u20137163. MCT-1509-0947 (2010).","DOI":"10.1158\/1535-7163.MCT-09-0947"},{"key":"55666_CR59","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1002\/jcb.23270","volume":"112","author":"R Matsushima-Nishiwaki","year":"2011","unstructured":"Matsushima-Nishiwaki, R. et al. Suppression by heat shock protein 20 of hepatocellular carcinoma cell proliferation via inhibition of the mitogen\u2010activated protein kinases and AKT pathways. Journal of cellular biochemistry 112, 3430\u20133439 (2011).","journal-title":"Journal of cellular biochemistry"},{"key":"55666_CR60","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.3390\/ijms15033507","volume":"15","author":"H-Y Wang","year":"2014","unstructured":"Wang, H.-Y., Yang, S.-L., Liang, H.-F. & Li, C.-H. HBx protein promotes oval cell proliferation by up-regulation of cyclin D1 via activation of the MEK\/ERK and PI3K\/Akt pathways. International journal of molecular sciences 15, 3507\u20133518 (2014).","journal-title":"International journal of molecular sciences"},{"key":"55666_CR61","first-page":"411","volume":"17","author":"C Stroescu","year":"2008","unstructured":"Stroescu, C. et al. Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma. J Gastrointestin Liver Dis 17, 411\u2013417 (2008).","journal-title":"J Gastrointestin Liver Dis"},{"key":"55666_CR62","first-page":"10235","volume":"8","author":"Y Luo","year":"2015","unstructured":"Luo, Y. et al. Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: a meta-analysis. International journal of clinical and experimental medicine 8, 10235 (2015).","journal-title":"International journal of clinical and experimental medicine"},{"key":"55666_CR63","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.taap.2018.12.020","volume":"364","author":"S Saber","year":"2019","unstructured":"Saber, S., Khalil, R. M., Abdo, W. S., Nassif, D. & El-Ahwany, E. Olmesartan ameliorates chemically-induced ulcerative colitis in rats via modulating NF\u03baB and Nrf-2\/HO-1 signaling crosstalk. Toxicology and Applied Pharmacology 364, 120\u2013132, https:\/\/doi.org\/10.1016\/j.taap.2018.12.020 (2019).","journal-title":"Toxicology and Applied Pharmacology"},{"issue":"12","key":"55666_CR64","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00210-019-01706-2","volume":"392","author":"Sameh Saber","year":"2019","unstructured":"Saber, S. et al. Telmisartan attenuates N-nitrosodiethylamine-induced hepatocellular carcinoma in mice by modulating the NF-\u03baB-TAK1-ERK1\/2 axis in the context of PPAR\u03b3 agonistic activity. Naunyn-Schmiedeberg\u2019s Archives of Pharmacology, https:\/\/doi.org\/10.1007\/s00210-019-01706-2 (2019).","journal-title":"Naunyn-Schmiedeberg's Archives of Pharmacology"},{"key":"55666_CR65","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.abb.2019.07.014","volume":"671","author":"S Saber","year":"2019","unstructured":"Saber, S., Basuony, M. & Eldin, A. S. Telmisartan ameliorates dextran sodium sulfate-induced colitis in rats by modulating NF-\u03baB signalling in the context of PPAR\u03b3 agonistic activity. Archives of Biochemistry and Biophysics 671, 185\u2013195, https:\/\/doi.org\/10.1016\/j.abb.2019.07.014 (2019).","journal-title":"Archives of Biochemistry and Biophysics"},{"key":"55666_CR66","first-page":"1","volume":"240","author":"R Abdel-Ghany","year":"2015","unstructured":"Abdel-Ghany, R. et al. Blockade of PGE2, PGD2 receptors confers protection against Prepatent schistosomiasis Mansoni in mice. Journal of the Egyptian Society of Parasitology 240, 1\u201310 (2015).","journal-title":"Journal of the Egyptian Society of Parasitology"},{"key":"55666_CR67","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s42269-018-0020-7","volume":"42","author":"S Saber","year":"2018","unstructured":"Saber, S. Angiotensin II: a key mediator in the development of liver fibrosis and cancer. Bulletin of the National Research Centre 42, 18, https:\/\/doi.org\/10.1186\/s42269-018-0020-7 (2018).","journal-title":"Bulletin of the National Research Centre"},{"key":"55666_CR68","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1365-2036.2011.04896.x","volume":"35","author":"M Pinter","year":"2012","unstructured":"Pinter, M. et al. The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma\u2013a pilot study. Alimentary pharmacology & therapeutics 35, 83\u201391 (2012).","journal-title":"Alimentary pharmacology & therapeutics"},{"key":"55666_CR69","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1002\/hep.26328","volume":"57","author":"MF Sprinzl","year":"2013","unstructured":"Sprinzl, M. F. et al. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology 57, 2358\u20132368 (2013).","journal-title":"Hepatology"}],"updated-by":[{"DOI":"10.1038\/s41598-022-17580-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55666-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55666-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55666-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T17:27:40Z","timestamp":1671298060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55666-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,13]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["55666"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-55666-x","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-022-17580-7","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,13]]},"assertion":[{"value":"9 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-022-17580-7","URL":"https:\/\/doi.org\/10.1038\/s41598-022-17580-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19095"}}